Rituximab Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Rituximab Growth

1. Broad, well-established indications across oncology and autoimmune diseases

• Rituximab is widely used in:
• Non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL)
• Rheumatoid arthritis and other autoimmune diseases
• Oncology remains the dominant revenue contributor, embedded in standard-of-care regimens.
• Multi-indication use -> large, diversified patient base
• Sustains demand despite competition

2. Strong historical commercial base (multi-billion dollar peak sales)

• Global sales (Roche):
• ~$5.3B in 2018 -> ~$5.0B in 2019 (oncology segment)
• Even after patent expiry, rituximab continues to generate significant global revenues across branded + biosimilars
• Large installed base of patients and prescribers -> durable revenue stream
• Established infrastructure supports continued uptake

3. Proven long-term efficacy and safety (clinical trust)

• Rituximab was the first monoclonal antibody approved for cancer, with decades of real-world data.
• Extensive long-term follow-up studies reinforce:
• Survival benefits in lymphoma
• Durable disease control in autoimmune disorders
• High physician confidence -> continued preference in treatment guidelines
• Acts as a benchmark therapy in anti-CD20 class

4. Expansion via biosimilars -> volume-driven growth

• Patent expiry:
• EU: ~2013 | US: ~2018
• Biosimilars have driven:
• 30-50% price reductions in some regions
• Increased accessibility in emerging markets
• While branded revenues decline, total patient volume increases significantly
• Expands global market penetration (especially Asia, Latin America)

5. Continued use in combination regimens and new treatment paradigms

• Rituximab remains a backbone in:
• Chemo-immunotherapy regimens (e.g., R-CHOP)
• Combination with targeted agents and immunotherapies
• Ongoing research explores:
• Optimized dosing
• New combinations

Rituximab Recent Developments

• In December 2025, In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data were presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

"Rituximab Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Rituximab for approved indication like Chronic lymphocytic leukaemia, Follicular lymphoma, Granulomatosis with polyangiitis, Idiopathic thrombocytopenic purpura, Lymphoproliferative disorders, and Microscopic polyangiitis; as well as potential indication like Mantle-cell lymphoma etc. in the 7MM. A detailed picture of Rituximab's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Rituximab for approved and potential indications. The Rituximab market report provides insights about Rituximab's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Rituximab performance, future market assessments inclusive of the Rituximab market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Rituximab sales forecasts, along with factors driving its market.

Rituximab Drug Summary

Rituximab is a chimeric monoclonal antibody developed by Genentech and Roche that targets the CD20 antigen expressed on B lymphocytes, leading to B-cell depletion through mechanisms such as complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis. It is widely used for the treatment of B-cell malignancies (including non-Hodgkin lymphoma and chronic lymphocytic leukemia) as well as autoimmune diseases such as rheumatoid arthritis, granulomatosis with polyangiitis, and pemphigus vulgaris. Administered via intravenous infusion (with some subcutaneous formulations available), rituximab has demonstrated durable efficacy in reducing disease activity and inducing remission; however, its use is associated with risks such as infusion reactions, infections, and rare cases of progressive multifocal leukoencephalopathy (PML). As one of the first successful targeted biologics, rituximab has become a cornerstone therapy across oncology and immunology, with numerous biosimilars expanding its global accessibility. The report provides Rituximab's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Rituximab Market Report

The report provides insights into:

• A comprehensive product overview including the Rituximab MoA, description, dosage and administration, research and development activities in approved indications like Chronic lymphocytic leukaemia, Follicular lymphoma, Granulomatosis with polyangiitis, Idiopathic thrombocytopenic purpura, Lymphoproliferative disorders, and Microscopic polyangiitis; as well as potential indication like Mantle-cell lymphoma etc..
• Elaborated details on Rituximab regulatory milestones and other development activities have been provided in Rituximab market report.
• The report also highlights Rituximab's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Rituximab market report also covers the patents information, generic entry and impact on cost cut.
• The Rituximab market report contains current and forecasted Rituximab sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Rituximab market report also features the SWOT analysis with analyst views for Rituximab in approved and potential indications.

Methodology:

The Rituximab market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Rituximab Analytical Perspective by DelveInsight

• In-depth Rituximab Market Assessment

This Rituximab sales market forecast report provides a detailed market assessment of Rituximab for approved indication like Chronic lymphocytic leukaemia, Follicular lymphoma, Granulomatosis with polyangiitis, Idiopathic thrombocytopenic purpura, Lymphoproliferative disorders, and Microscopic polyangiitis; as well as potential indication like Mantle-cell lymphoma etc. in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Rituximab sales data uptil 2034.

• Rituximab Clinical Assessment

The Rituximab market report provides the clinical trials information of Rituximab for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Rituximab Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Rituximab Market Potential & Revenue Forecast

• Projected market size for the Rituximab and its key indications
• Estimated Rituximab sales potential (Rituximab peak sales forecasts)
• Rituximab Pricing strategies and reimbursement landscape

Rituximab Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Rituximab Market positioning compared to existing treatments
• Rituximab Strengths & weaknesses relative to competitors

Rituximab Regulatory & Commercial Milestones

• Rituximab Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Rituximab Clinical Differentiation

• Rituximab Efficacy & safety advantages over existing drugs
• Rituximab Unique selling points

Rituximab Market Report Highlights

• In the coming years, the Rituximab market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Rituximab companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Rituximab's dominance.
• Other emerging products for Chronic lymphocytic leukaemia, Follicular lymphoma, Granulomatosis with polyangiitis, Idiopathic thrombocytopenic purpura, Lymphoproliferative disorders, and Microscopic polyangiitis; as well as potential indication like Mantle-cell lymphoma etc. are expected to give tough market competition to Rituximab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Rituximab in approved and potential indications.
• Analyse Rituximab cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Rituximab sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Rituximab in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Rituximab? How strong is Rituximab's clinical and commercial performance?
• What is Rituximab's clinical trial status in each individual indications such as Chronic lymphocytic leukaemia, Follicular lymphoma, Granulomatosis with polyangiitis, Idiopathic thrombocytopenic purpura, Lymphoproliferative disorders, and Microscopic polyangiitis; as well as potential indication like Mantle-cell lymphoma etc. and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Rituximab Manufacturers?
• What are the key designations that have been granted to Rituximab for approved and potential indications? How are they going to impact Rituximab's penetration in various geographies?
• What is the current and forecasted Rituximab market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Rituximab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Rituximab for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Rituximab? What is the duration of therapy and what are the geographical variations in cost per patient?